COSMO Pharmaceuticals N.V. header image

COSMO Pharmaceuticals N.V.

COPN

Equity

ISIN NL0011832936 / Valor 32590356

SIX Swiss Exchange (2025-10-21)
CHF 68.50+0.93%

COSMO Pharmaceuticals N.V.
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of gastrointestinal diseases. The company has successfully brought to market six approved drugs and two medical devices, addressing unmet medical needs in this therapeutic area. COSMO Pharmaceuticals is involved in the entire product lifecycle, from identifying medical needs and managing product development to obtaining regulatory approvals. The company licenses its approved products to partners with strong marketing and sales capabilities, ensuring effective market penetration. Additionally, COSMO offers a range of services related to pharmaceutical production, including the assessment of manufacturing processes, technology transfer, evaluation of product stability, market testing and release, and the preparation of necessary documentation for product registration.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (15.10.2025):

Cosmo Pharmaceuticals N.V. reported a strong financial performance in the fiscal year 2024, showcasing exceptional revenue growth and significant strategic advancements that pave the way for sustained corporate development.

Financial Performance

The consolidated and audited financial results for 2024 highlight Cosmo Pharmaceuticals' robust financial health and effective management throughout the fiscal year.

Revenue Growth

The company achieved exceptional revenue growth in 2024, reflecting successful market strategies and increased demand for its innovative healthcare products.

Dividend Proposal

The Board of Directors proposed a dividend distribution of €2.05 per share for 2024, up from €2.00 per share in the previous year, demonstrating a commitment to shareholder value.

Strategic Advancements

Significant strategic advancements were made in 2024, including collaborations with leading partners and the development of a clear roadmap for future corporate initiatives.

Summarized from source with an LLMView Source

Key figures

-11.5%1Y
26.6%3Y
-21.8%5Y

Performance

35.3%1Y
30.2%3Y
31.5%5Y

Volatility

Market cap

1308 M

Market cap (USD)

Daily traded volume (Shares)

16,311

Daily traded volume (Shares)

1 day high/low

63.8 / 61.5

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Johnson & Johnson
Johnson & Johnson Johnson & Johnson Valor: 943981
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.26%USD 193.72
Camurus AB
Camurus AB Camurus AB Valor: 30510553
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.76%SEK 665.50
GSK PLC
GSK PLC GSK PLC Valor: 120042705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.48%USD 44.12
Smith & Nephew PLC
Smith & Nephew PLC Smith & Nephew PLC Valor: 1111046
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.03%USD 36.33
Ambu A/S
Ambu A/S Ambu A/S Valor: 39639588
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%DKK 105.30
Alk-Abello A/S
Alk-Abello A/S Alk-Abello A/S Valor: 117689788
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.38%DKK 215.00
H. Lundbeck A/S
H. Lundbeck A/S H. Lundbeck A/S Valor: 119252587
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.40%DKK 45.68
Sanofi SA
Sanofi SA Sanofi SA Valor: 699381
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.17%EUR 86.58
Eurofins Scientific SE
Eurofins Scientific SE Eurofins Scientific SE Valor: 58317129
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.21%EUR 63.90
AstraZeneca PLC
AstraZeneca PLC AstraZeneca PLC Valor: 163523
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.97%USD 83.87